T.Man Pharmaceutical PCL (BKK: TMAN)

T.Man Pharmaceutical PCL Income Statement

Financials in millions THB. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	2,186	1,972	2,017	1,260	895.52
Other Revenue	10.74	7.81	8.05	3.43	5.26
Revenue	2,197	1,980	2,025	1,263	900.78
Revenue Growth (YoY)	15.41%	-2.20%	60.26%	40.25%	-
Cost of Revenue	1,172	1,003	923.57	861.26	572.32
Gross Profit	1,025	976.84	1,101	402.08	328.46
Selling, General & Admin	508.74	496.43	452.32	313.35	248.35
Operating Expenses	504.99	451.8	492.88	321.07	254.23
Operating Income	519.71	525.04	608.21	81.01	74.23
Interest Expense	-12.61	-14.85	-16.98	-7.18	-9.09
Pretax Income	507.1	510.19	591.23	73.83	65.15
Income Tax Expense	73.82	79.1	118.71	17.44	5.25
Net Income	433.28	431.09	472.52	56.39	59.89
Net Income to Common	433.28	431.09	472.52	56.39	59.89
Net Income Growth	4.15%	-8.77%	737.91%	-5.84%	-
Shares Outstanding (Basic)	317	275	250	72	67
Shares Outstanding (Diluted)	317	275	250	72	67
Shares Change (YoY)	18.78%	10.31%	246.21%	8.20%	-
EPS (Basic)	1.37	1.56	1.89	0.78	0.90
EPS (Diluted)	1.37	1.56	1.89	0.78	0.90
EPS Growth	-12.32%	-17.29%	142.02%	-12.98%	-
Free Cash Flow	313.1	62.15	289.02	196.49	128.83
Free Cash Flow Per Share	0.99	0.23	1.16	2.72	1.93
Dividend Per Share	0.545	0.036	-	-	-
Gross Margin	46.65%	49.33%	54.38%	31.83%	36.46%
Operating Margin	23.66%	26.52%	30.04%	6.41%	8.24%
Profit Margin	19.73%	21.77%	23.34%	4.46%	6.65%
Free Cash Flow Margin	14.25%	3.14%	14.27%	15.55%	14.30%
EBITDA	611.11	612.32	678.68	148.29	143.51
EBITDA Margin	27.82%	30.92%	33.52%	11.74%	15.93%
D&A For EBITDA	91.4	87.28	70.48	67.28	69.28
EBIT	519.71	525.04	608.21	81.01	74.23
EBIT Margin	23.66%	26.52%	30.04%	6.41%	8.24%
Effective Tax Rate	14.56%	15.50%	20.08%	23.62%	8.06%
Revenue as Reported	2,197	1,980	2,025	1,263	900.78
Advertising Expenses	-	98	89	52	34

Source: S&P Capital IQ. Standard template. Financial Sources.